CClinicalTrials.gg
Sign In
CompletedNCT03631446Updated Jan 18, 2022

Drug Use-Results Survey on Picoprep® Combination Powder

An observational study in Bowel Cleansing, sponsored by Ferring Pharmaceuticals. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2022-01-18.

Sponsored by Ferring Pharmaceuticals · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,298
Sex
All
01

Study summary

The purpose of this survey is to confirm safety and efficacy with patients who are administered the Picoprep® for cleansing of intestinal contents for preparation of colonoscopy and colorectal surgery.

02

Conditions studied

  • Bowel Cleansing
03

In context

Lead sponsor

Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients being prepared for colonoscopy and colorectal surgery

Eligibility criteria

Inclusion Criteria:

Patients who are administered the Picoprep® for cleansing of intestinal contents for preparation of colonoscopy and colorectal surgery.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,298 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients administered Picoprep® for bowel cleansing

    Patients administered Sodium Picosulfate, Magnesium Oxide and Citric Acid for bowel cleansing

    Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid

Interventions

  • DrugSodium Picosulfate, Magnesium Oxide and Citric Acid

    Combination powder for oral solution

    Also known as: Picoprep®

06

What researchers measure

Primary outcomes

  1. Bowel cleansing assessment for colonoscopy

    Assessment of each part of large intestine using a bowel cleanliness rating scale

    Time frame: 48 hours after drug administration

  2. Bowel cleansing assessment for colorectal surgery

    Assessment of each part of large intestine using a bowel cleanliness rating scale

    Time frame: 48 hours after drug administration

07

Study locations

1 site
  • Investigational Site (there may be other sites in this country)
    Shibuya, Tokyo, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03631446
Lead sponsor
Ferring Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 15, 2018
Start date
Aug 29, 2017
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Last update
Jan 18, 2022

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Ferring Pharmaceuticals

Start the discussion